-
-
Call more information
660-596-2224 -
Authors: Eileen Nguyen, MD, PhD et al Anesthesiology June 2023. Background Pharmacological manipulations directed at the periaqueductal gray have demonstrated the importance of the mu-opioid receptor in modulating reflexive responses to nociception. We hypothesized that a supraspinal pathway centered on neurons in the periaqueductal gray containing the mu-opioid receptor could modulate nociceptive and itch behaviors. […]
Read MoreAuthors: Michael M. Todd, M.D.; Aaron F. Kopman, M.D. Anesthesiology July 2023, Vol. 139, 1–3. “Their observations […] indicate that clinicians who do not see the necessity for quantitative or objective neuromuscular monitoring when reversing residual block with sugammadex need to rethink their position.” In the current issue of Anesthesiology, Bowdle et al. report the results of an observational […]
Read MoreAuthor: Jeanna D. Blitz, M.D., F.A.S.A., D.F.P.M. Anesthesiology July 2023, Vol. 139, 91–103. The preanesthesia evaluation is the process of clinical assessment that precedes the delivery of anesthesia care. It provides the foundation for creating the perioperative anesthesia and pain management plan. The goal is to identify any factors that would prevent the patient from safely having […]
Read MoreAuthors: T. Andrew Bowdle, M.D., Ph.D., F.A.S.E. et al Anesthesiology July 2023, Vol. 139, 6–15. Background The dose of sugammadex recommended by the manufacturer for reversal of rocuronium is 2 mg/kg when the train-of-four count is 2 or more and 4 mg/kg when it is less than 2 but there is a posttetanic count of at least 1. […]
Read MoreAuthors: Patrick Forrest, MD et al ASA Monitor July 2023, Vol. 87, 1–5. Many readers may now be familiar with the new ASA practice guidelines for monitoring and antagonism of neuromuscular blockade that were published this past January (Anesthesiology 2023;138:13-41). For those who are not, this article may serve as a brief overview of the advances […]
Read MoreASA Monitor April 2023, Vol. 87, 17. UpToDate® and ASA Monitor are collaborating to present select content abstracts on “What’s New in Anesthesiology.” UpToDate is an evidence-based, clinical support resource used worldwide by health care practitioners to make decisions at the point of care. For complete, current “What’s New” content, or to become a subscriber for full content access, […]
Read MoreASA Monitor July 2023, Vol. 87, 10. A 45-year-old woman is scheduled to undergo a bilateral mastectomy for metastatic breast cancer. According to a recent study of patients undergoing breast cancer surgery with general anesthesia maintained with propofol or volatile agents, which of the following MOST likely describes overall survival with use of propofol compared to […]
Read MoreASA Monitor July 2023, Vol. 87, 7. Which of the following immunosuppressive drugs is MOST likely to cause renal dysfunction? □ (A) Tacrolimus □ (B) Mycophenolate mofetil □ (C) Basiliximab Immunosuppressant drugs are used to prevent or treat allograft rejection. Most of these drugs act during the induction phase of the immunological response, reducing lymphocyte proliferation. Some of them […]
Read MoreAuthors: Judith Jurin Semo, JD; Shena J. Scott, MBA, FACMPE ASA Monitor July 2023, Vol. 87, 17–18. Restrictive covenants or noncompetes in employment are a contentious topic (ASA Monitor 2020;84:1-18). If a proposed rule issued in January 2023 by the Federal Trade Commission (FTC) is adopted, most employers in the United States will be foreclosed from requiring […]
Read MoreAuthor: Zachary Deutch, MD, FASA ASA Monitor July 2023, Vol. 87, 13–15. The answer to the question in the title is rhetorical, as it will be in the eye of the beholder. Each ASA member has his or her own unique practice situation, personal disposition, and life priorities, so the realities one perceives as “bad” might […]
Read More